fosun pharma’s new drug for gout received nmpa approval for clinical trial registration -凯发k8娱乐app下载

fosun pharma’s new drug for gout received nmpa approval for clinical trial registration -凯发k8娱乐app下载

2020-03-08

fosun pharma’s new drug for gout received nmpa approval for clinical trial registration


【9 march, hong kong】 recently, fochon pharmaceuticals., ltd., (“fochon pharma”), a subsidiary of shanghai fosun pharmaceutical (group) co., ltd. (“fosun pharma”; stock codes: 600196.sh, 02196.hk) received application acceptance notification (acceptance nos. cxhl2000046 (guo) and cxhl2000047 (guo)) for clinical trial registration from the national medical products administration (nmpa) for its fcn-207 tablet, a new drug for the treatment of hyperuricemia or gout

fcn-207 tablet is an innovative small molecule chemical drug developed by fosun pharma and intended for the treatment of hyperuricemia or gout. as of january 2020, fosun pharma’s accumulated r&d input in fcn-207 tablets totalled approximately rmb 20.3 million (unaudited) for the current stage. 

so far, medicines with the same targets as fcn-207 tablets are available around the globe; however, there is still no such drug with independent intellectual property rights on the mainland chinese market.